AstraZeneca (AZN) Stock Price, News & Analysis

Company Overview

AstraZeneca is a global biopharmaceutical company focused on the discovery, development and commercialization of prescription medicines. The company’s research efforts concentrate on four primary therapy areas: oncology; cardiovascular, renal & metabolism; respiratory & immunology; and rare diseases. By combining a robust pipeline with collaborations across academia and industry, AstraZeneca seeks to address unmet medical needs and bring innovative treatments to patients worldwide.

In oncology, AstraZeneca markets several targeted therapies and immuno-oncology agents designed to treat various cancers, including lung, breast and hematological malignancies. Its cardiovascular, renal & metabolism portfolio features treatments for conditions such as heart failure, chronic kidney disease and diabetes. The respiratory & immunology segment offers therapies for asthma, chronic obstructive pulmonary disease and other inflammatory disorders. The company also advances specialty medicines for rare diseases through strategic partnerships and internal development programs.

Formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group PLC, AstraZeneca is headquartered in Cambridge, England. The company operates in over 100 countries, with major research centres, manufacturing sites and commercial offices across Europe, North America, Asia and Latin America. This global footprint supports rapid clinical development, regulatory engagement and product launches.

Under the leadership of Chief Executive Officer Pascal Soriot, AstraZeneca has emphasized scientific innovation, sustainable growth and digital transformation. The company continues to invest in advanced research platforms, real-world evidence generation and strategic alliances to expand its pipeline and deliver long-term value for patients, healthcare systems and shareholders.

Key Stats

• Today's Range: $70.50 to $71.15
• 50-Day Range: $66.23 to $75.00
• 52-Week Range: $61.24 to $87.68
• Volume: 2.73 million shs
• Average Volume: 5.27 million shs
• Market Capitalization: $220.60 billion
• P/E Ratio: 28.57
• Dividend Yield: 2.90%
• Price Target: $89.00
• Consensus Rating: Moderate Buy

AstraZeneca Stock Analysis - MarketRank™

AstraZeneca scored higher than 75% of companies evaluated by MarketBeat, and ranked 258th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

AstraZeneca has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

AstraZeneca has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 10.86%

Earnings Growth

Earnings for AstraZeneca are expected to grow by 10.86% in the coming year, from $4.51 to $5.00 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AstraZeneca is 28.57, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.92.

Price to Earnings Ratio vs. Sector

The P/E ratio of AstraZeneca is 28.57, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.10.

Price to Earnings Growth Ratio

AstraZeneca has a PEG Ratio of 1.32. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

AstraZeneca has a P/B Ratio of 5.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.22% of the float of AstraZeneca has been sold short.

Short Interest Ratio / Days to Cover

AstraZeneca has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in AstraZeneca has recently decreased by 8.59%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

AstraZeneca pays a meaningful dividend of 2.87%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

AstraZeneca does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of AstraZeneca is 82.73%. Payout ratios above 75% are not desirable because they may not be sustainable.

Dividend Sustainability

Based on earnings estimates, AstraZeneca will have a dividend payout ratio of 41.20% next year. This indicates that AstraZeneca will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.22% of the float of AstraZeneca has been sold short.

Short Interest Ratio / Days to Cover

AstraZeneca has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in AstraZeneca has recently decreased by 8.59%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.36

News Sentiment

AstraZeneca has a news sentiment score of 1.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.00 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 21 news articles for AstraZeneca this week, compared to 26 articles on an average week.

Search Interest

29 people have searched for AZN on MarketBeat in the last 30 days. This is an increase of 53% compared to the previous 30 days.

MarketBeat Follows

6 people have added AstraZeneca to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, AstraZeneca insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 20.35% of the stock of AstraZeneca is held by institutions.

AZN Stock Analysis - Frequently Asked Questions

How have AZN shares performed this year?

AstraZeneca's stock was trading at $65.52 on January 1st, 2025. Since then, AZN stock has increased by 8.6% and is now trading at $71.13.

How were AstraZeneca's earnings last quarter?

AstraZeneca PLC (NASDAQ:AZN) released its earnings results on Tuesday, April, 29th. The company reported $1.24 EPS for the quarter, beating the consensus estimate of $1.10 by $0.14. The business's quarterly revenue was up 7.2% on a year-over-year basis.
Read the conference call transcript.

When did AstraZeneca's stock split?

Shares of AstraZeneca split on Monday, July 27th 2015.The 2-1 split was announced on Friday, June 26th 2015. The newly created shares were issued to shareholders after the closing bell on Friday, July 24th 2015. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Does AstraZeneca have any subsidiaries?

AstraZeneca subsidiaries include Alexion Pharmaceuticals, Takeda Respiratory Business, AcertaPharma, ZS Pharma, Almirall, Pearl Therapeutics, Omthera Pharmaceuticals, and others.

Who are AstraZeneca's major shareholders?

Top institutional investors of AstraZeneca include Swedbank AB (0.13%), Assenagon Asset Management S.A. (0.04%), Professional Advisory Services Inc. (0.01%) and Wealth Enhancement Advisory Services LLC (0.01%).
View institutional ownership trends.

How do I buy shares of AstraZeneca?

Shares of AZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of AstraZeneca own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AstraZeneca investors own include Chevron (CVX), BlackRock (BLK), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Bristol Myers Squibb (BMY) and Tesla (TSLA).

Company Calendar

• Last Earnings: 4/29/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 7/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AZN
• CIK: 901832
• Web: www.astrazeneca.com
• Phone: 442037495000
• Fax: 44-12-2335-2858
• Employees: 94,300
• Year Founded: 1999

Price Target and Rating

• Average Price Target for AstraZeneca: $89.00
• High Price Target: $97.00
• Low Price Target: $75.00
• Potential Upside/Downside: +25.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.49
• Trailing P/E Ratio: 28.57
• Forward P/E Ratio: 15.77
• P/E Growth: 1.32
• Net Income: $7.04 billion
• Net Margins: 14.14%
• Pretax Margin: 16.90%
• Return on Equity: 33.14%
• Return on Assets: 12.83%

Debt

• Debt-to-Equity Ratio: 0.65
• Current Ratio: 0.90
• Quick Ratio: 0.70

Sales & Book Value

• Annual Sales: $54.07 billion
• Price / Sales: 4.08
• Cash Flow: $6.23 per share
• Price / Cash Flow: 11.41
• Book Value: $13.18 per share
• Price / Book: 5.40

Miscellaneous

• Outstanding Shares: 3,101,320,000
• Free Float: N/A
• Market Cap: $220.60 billion
• Optionable: Optionable
• Beta: 0.37